Diabetes Technology
On this page
Direct answer
Time in range — the percentage of sensor glucose readings between 70 and 180 mg/dL — has become the headline glucose metric, with the international consensus target of more than 70% time in range alongside less than 4% below 70 mg/dL and under 1% below 54 mg/dL. Continuous glucose monitoring (CGM) is divided into real-time systems with alarms and intermittently scanned ("flash") systems such as the sensor-based reader or phone-scan devices, worn for 10–14 days on the arm or abdomen. Insulin pumps (continuous subcutaneous insulin infusion) deliver rapid-acting insulin continuously, and modern hybrid closed-loop systems adjust basal delivery automatically using sensor readings. Together they benefit type 1 diabetes, hypoglycaemia unawareness and pregnancy above all.
What you must remember
- CGM targets: >70% time in range (70–180 mg/dL), <4% below 70 mg/dL, <1% below 54 mg/dL, glucose coefficient of variation ≤36%.
- HbA1c equivalence: each 10% shift in time in range approximates a 0.5–0.6% HbA1c change (an HbA1c of 7% corresponds roughly to an estimated glucose of 154 mg/dL).
- Glucose management indicator (GMI) is a CGM-derived HbA1c estimate, used when haemoglobin variants or anaemia distort HbA1c.
- Real-time CGM with alarms suits hypoglycaemia unawareness and type 1 diabetes; flash CGM suits stable type 2 patients wanting pattern data without alarms.
- Standard CGM metrics review needs 14 days of ≥70% sensor wear for a representative report.
- Pumps (CSII): rapid analogue insulin only; basal rates programmable by the hour; patients must still carb-count and bolus.
- Hybrid closed-loop systems (sensor + pump + algorithm) automatically adjust basal and give auto-correction boluses, reducing nocturnal hypoglycaemia.
- Sensor glucose lags blood glucose by 5–15 minutes — during rapid change, blood glucose meter readings take precedence, and sensors read "flat" when readings conflict with symptoms.
A walk through using the technology
Consider a 26-year-old with type 1 diabetes, HbA1c 8.4%, two severe nocturnal hypoglycaemic episodes and reduced awareness on basal-bolus injections. Start real-time CGM: within the first fortnight the downloads reveal repeated 3 a.m. readings in the 50s mg/dL and post-breaknoon spikes — invisible on quarterly HbA1c. The immediate fixes are structural: lower the night basal rate, shift evening exercise, and set a low-glucose alarm at 70 mg/dL. Because hypoglycaemia unawareness persists, a pump with predictive low-glucose suspend is a reasonable upgrade; if she is motivated, a hybrid closed-loop automates the overnight hours, where it performs best.
Reading a CGM report is an exam-ready skill: state the 14-day average, time in range, time below range, coefficient of variation and patterns by time of day before touching any dose.
For a stable type 2 patient on basal insulin, an intermittently scanned sensor worn two weeks each quarter generates the same pattern intelligence at lower cost. In pregnancy with pre-existing diabetes, tighter targets apply — roughly 70–140 mg/dL with CGM time in range >70% — and continuous use is recommended where available. Indian access remains uneven and largely private-pay, so a practical middle path — structured self-monitoring plus periodic professional CGM — is a legitimate answer when cost frames the question, as it often does in Indian clinical viva.
Where students slip
The reflexive error is treating CGM as a fancier glucometer: the value is pattern data and alarms, not single numbers, and decisions come from 14-day reports rather than spot readings. The second slip is trusting the sensor during rapid glucose change — sensor glucose trails blood glucose, so a symptomatic patient with a "normal" sensor reading needs a fingerstick. Third, candidates forget pump rules: only rapid-acting insulin is used, so any delivery failure (kinked cannula, air bubble, empty reservoir) tips quickly toward ketoacidosis, and pump patients need a written backup plan of basal-bolus injections.
Frequently asked questions
What are the standard CGM targets for adults with diabetes?
More than 70% of readings in 70–180 mg/dL, less than 4% at 70 mg/dL or below, less than 1% below 54 mg/dL, and a coefficient of variation of 36% or less. Pregnancy and older high-risk patients use modified targets.
How does flash glucose monitoring differ from real-time CGM?
Flash systems require the user to scan the sensor for a reading and have no automatic alarms; real-time systems stream continuously and alert for highs and lows. Both show trend arrows, which guide action more than single values.
Who benefits most from insulin pump therapy?
Motivated type 1 patients with suboptimal HbA1c on injections, disabling dawn phenomenon, or hypoglycaemia unawareness, and those able to count carbohydrates and respond to alarms. Pumps demand training and daily engagement.
Can CGM replace HbA1c monitoring?
Not entirely — HbA1c still anchors long-term risk correlation — but GMI from CGM approximates it, and CGM is superior when anaemia, haemoglobinopathy or pregnancy make HbA1c unreliable.
Why can sensor glucose disagree with a fingerstick during rapid change?
Interstitial fluid glucose lags blood glucose by roughly 5–15 minutes, so during rapid rise or fall the sensor trails. When symptoms and sensor conflict, trust the meter.